# First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

> **NCT07529717** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 42 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** AZD8359
- **DRUG:** AZD8359
- **DRUG:** AZD8359
- **DRUG:** AZD8359

## Key facts

- **NCT ID:** NCT07529717
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-09
- **Primary completion:** 2027-10-11
- **Final completion:** 2027-10-11
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07529717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07529717, "First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07529717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*